Abcam Revenue and Competitors

Boston, MA USA

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Abcam's estimated annual revenue is currently $297.7M per year.(i)
  • Abcam's estimated revenue per employee is $105,830
  • Abcam's current valuation is $4.1B. (January 2022)

Employee Data

  • Abcam has 2813 Employees.(i)
  • Abcam grew their employee count by -2% last year.

Abcam's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
Head Kits ManufacturingReveal Email/Phone
3
Head Sales and Service Training and KnowledgeReveal Email/Phone
4
VP, Innovation Programme managementReveal Email/Phone
5
VP Global WorkplaceReveal Email/Phone
6
VP Digital CustomerReveal Email/Phone
7
General Counsel and Company SecretaryReveal Email/Phone
8
Head OperationsReveal Email/Phone
9
VP Business, Process & Operational ExcellenceReveal Email/Phone
10
VP, Customer & Commercial OperationsReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$130.7M8435%N/AN/A
Add Company

What Is Abcam?

Abcam is on a mission "...to build the largest online catalog of the best antibodies in the world" Video: More than antibodies Larger version of 'Video: More than antibodies' » Abcam supplies the best products... We make our own antibodies as well as sourcing other excellent products from a variety of suppliers. This means we are able to add 600-800 new products every month and ensures we bring customers the very best products available regardless of source. Our products cover research areas such as Cancer, Cardiovascular, Chromatin and Nuclear Signaling, Immunology, Neuroscience, and Stem Cells, and includes a growing range of non-primary antibody products such as secondary antibodies, kits, proteins, peptides, and lysates. ...and provides the best service Whether you buy online, by telephone, or fax, we want you to have the best experience from beginning to end. Our online search facility shows what we offer across all our product ranges, and our comprehensive datasheets provide you with all the essential information you need to make that important decision. We know information about applications and species, and supporting data such as references, images and reviews are crucial for you to find the right product, so as soon as we know something new about one of our products, we update our online datasheet. We provide expert scientific support for all of our products to enable you to achieve the result you should expect (we have over 40 PhDs in-house to answer your queries). We guarantee that all products will work as described on our datasheets, or we will give you a replacement or refund. We ship all around the world from our offices in the UK, US, Japan and Hong Kong, with next day delivery to most of Europe and North America. If, for any reason, an item is not in stock, we will keep you informed of your order and aim to get it to you as quickly as possible.

keywords:N/A

N/A

Total Funding

2813

Number of Employees

$297.7M

Revenue (est)

-2%

Employee Growth %

$4.1B

Valuation

N/A

Accelerator

Abcam News

2022-04-17 - Europe CRISPR Gene Editing Market to 2031 - Featuring ...

Europe CRISPR Gene Editing Market to 2031 - Featuring Abcam, Agilent Technologies and Lonza Group Among Others - ResearchAndMarkets.com.

2022-04-06 - Year In Review: 2021 – Abcam plc

“Despite the continued disruption of COVID-19, we have seen sustained progress during the period as we continue to deliver on the growth strategy announced...

2022-03-30 - Abcam the most awarded company at 2022 industry awards

As a global life sciences company, Abcam identifies, develops, and distributes high-quality biological reagents and tools that are crucial to...

2021-10-27 - Abcam completes $340m strategic acquisition and expands kit capacity and capability

- Completing $340m strategic acquisition of BioVision - Expanding facilities in Eugene, further growing kits and assays portfolio - Supporting the growing demand of the sector and accelerating execution of strategic plan CAMBRIDGE, England, Oct. 27, 2021 /PRNewswire/ -- Abcam (AIM:ABC; NASDAQ ...

2021-07-13 - Abcam : opens new US facility in Boston, MA

CAMBRIDGE, July 13, 2021 /PRNewswire/ -- Abcam (AIM: ABC) (NASDAQ: ABCM), a global innovator in life sciences reagents and tools, today announces the opening of a major new site in Waltham, MA. The new facility is a central component of Abcam's growth in the United States, reinforcing its commi ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$300M28729%N/A
#2
$1456.7M3153-4%N/A
#3
$300M32269%N/A
#4
N/A334052%N/A
#5
$497.4M34834%N/A